Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nereus Pharmaceuticals has started enrollment in a Phase Ib study evaluating the proteasome inhibitor NPI-0052 in combination with vorinostat in patients with selected solid tumor malignancies.
Subscribe to our email newsletter
The open-label study will enroll approximately 40 patients with advanced non-small cell lung cancer, pancreatic cancer or melanoma for whom standard approved therapy is not available. The study follows on positive outcomes from preclinical studies of the combined agents and clinical trials with NPI-0052. Upon successful completion of the Phase Ib trial and determination of the recommended doses for the combined agents, Nereus expects to advance the program into Phase II trials in 2009.
Matthew Spear, chief medical officer of Nereus, said: “Combining complementary anticancer agents to maximize their effects is proven strategy that we are excited to explore with our internally-discovered, second-generation proteasome inhibitor NPI-0052, and we have been particularly impressed with the preclinical results from this combination.”